BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This Phase 2 study will establish the safety and efficacy profile of LMY-920.
Trial Details
NCT Number NCT07771361
Lead Sponsor Luminary Therapeutics
Conditions
(from sponsor)		 Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin Lymphoma, B-cell, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma in Remission
Related terms Lymphoma, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Recurrence
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov